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Fructose 2,6-bisphosphate is present in the rat mammary gland, rising from a value of 1.4 nmol/g in 
pregnancy to4.3 nmol/g tissue at 14 days lactation; the equivalent values calculated/ml intracellular water 
are 5.2 and 11.6 nmol, respectively. The tissue content of fructose 6-phosphate, fructose 1,6-bisphosphate, 
ATP and phosphoenolpyruvate remain relatively constant in the transition from pregnancy to the height 
of lactation. The changes in AMP, cyclic AMP, and citrate content of the mammary gland during lactation 
are such as to promote an increase in fructose 2,dbisphosphate formation and flux through 
phosphofructokinase. 
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1. INTRODUCTION 
During the lactation cycle the mammary gland 
changes from a metabolism geared to a growth 
phase during pregnancy to one of intense biosyn- 
thetic activity and secretion during lactation. In the 
rat the milk yield increases almost linearly during 
lactation by some 6-fold from the 1st to the 14th 
day of lactation [l] and the glucose utilization at 
this peak of lactation may rise to as much as 
30 mmo1/24 h [2]. The increased demand for 
energy and for precursors for lipid synthesis, both 
acetyl-CoA and glycerol 3-phosphate, during lac- 
tation requires an increased flux through PFKl 
(EC 2.7.1.11). 
Recent studies have emphasized the importance 
of Fru-2,6-P* in the regulation of PFKl (see [3,4]). 
It was, therefore, of interest o determine the pro- 
file of change of Fru-2,6-Pz in the rat mammary 
Abbreviations: Fru-1,6-Pz, fructose 1,dbisphosphate; 
Fru-2,6-Pz, fructose 2,dbisphosphate; PFKl, 6-phos- 
phofructo-1-kinase; PFKZ, 6-phosphofructo-2-kinase 
gland in pregnancy and lactation and to compare 
these changes with those of other known effecters 
of PFKl and PFKZ. 
2. MATERIALS AND METHODS 
2.1. Animals 
Primiparous rats of the Wistar strain were taken 
on the 21st day of pregnancy or the 1st or 14th day 
of lactation; the litter size was restricted to 8 pups 
in the lactating groups. The rats were anaesthetized 
with sodium pentobarbital(60 mg/kg body wt, ad- 
ministered i.p.) and the abdominal mammary 
glands quickly removed and freeze clamped, using 
liquid nitrogen, for measurement of metabolites, 
including Fru-2,6-Pz. 
2.2. Materials 
Fru-2,6-Pz was a gift from Dr E. van Schaf- 
tingen (Univqsity of Louvain, Belgium). En- 
zymes, substrates and cofactors, used in the 
measurement of metabolites and assay of PFKl, 
were obtained from Boehringer Corp. London Ltd 
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(Lewes, England). Potato tuber PPi: fructose-d 
phosphate I-phosphotransferase, used in the assay 
of Fru-2,6-Pz, was prepared as in [5]. 
2.3. Measurement of metabolites 
Mammary gland Fru-2,6-P2 was assayed by its 
stimulatory action on potato tuber PPr : fructoseB- 
phosphate I-phosphotransferase as in [5], using 
neutralised alkaline extracts of mammary gland. 
Sugar phosphates, citrate, adenine nucleotides and 
cyclic AMP were measured in neutralised per- 
chloric acid extracts of mammary gland as in 
[6-81. 
2.4. Assay of phosphofructokinase (PFKl) 
Mammary gland homogenates were prepared in 
a medium containing 0.25 M sucrose, 20 mM 
triethanolamine buffer (pH 7.4) and 0.1 mM 
dithiothreitol and the activity of PFKl was deter- 
mined spectrophotometrically as in [9] using the 
dialysed high-speed supernatant fraction prepared 
by centrifugation at 105000 x g for 40 min. The 
present reported activity of PFKI is closely similar 
to that reported in [IO] for lactating rat mammary 
Table I 
gland. One unit of activity is defined as the conver- 
sion of 1 pmol substrate/min at 25°C. 
2.5. Expression of results 
The values for metabolites are given as nmol/g 
tissue and as nmol/ml intracellular water. The lat- 
ter mode is used in order to facilitate comparison 
of mammary gland content of Fru-2,6-P2 and 
sugar phosphates at different stages of lactation 
and with reported values for other tissues e.g. 
liver. The method of converting metabolite con- 
tent/g mammary gland to metabolite concentra- 
tion/ml intracellular water 
described [1,7,11]. 
3. RESULTS 
3.1. Rat mammary gland 
2,&bisphosphate and 
during lactation 
Fru-2,6-P2 appears to be 
has previously been 
content of fructose 
phosphofructokinase 
present in significant _ _. 
amounts in the rat mammary gland in pregnancy 
and lactation (table 1). Based on the level of 
Fru-2,6-P2/g tissue, uncorrected for the milk or fat 
Changes in fructose 2,6_bisphosphate in rat mammary gland during lactation 
and the relationship to phosphofructokinase (PFKl) activity 
Pregnant 
(20 days) 
Lactating 
1 day 14 days 
Mammary gland weighta (g) 3.71 i 0.23 3.56 f 0.32 4.32 f 0.35 
Fru-2,6-P2 content 
nmol/g gland 1.4 i 0.1 2.4 f 0.2 4.1 * 0.4 
nmol/ml intracellular HtOb 5.2 f 0.3 6.2 f 0.6 11.6 + 1.1 
PFKl activity 
units/g gland 1.31 f 0.10 1.79 f 0.15 4.89 f 0.21 
Relationship of PFKl to Fru-2,6-PrC 
PFKl/Fru-2,6-P2 0.96 f 0.09 0.75 f 0.09 1.18 zt 0.10 
* Weight of abdominal mammary gland from one side only 
b Calculated as in [1,7,11], correction being made for the milk and fat content 
of the gland 
’ Quotient calculated from PFKl (activity/g) and Fru-2,6-P2 content/g 
mammary gland 
Values given are the means + SE of not less than 5 values 
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content of the gland, there is a 3-fold increase from pregnancy to the peak of lactation. Further, the 
late pregnancy to the height of lactation at 14 days. concentration of Fru-2,6-P2 present in the mam- 
If the results are expressed/ml intracellular water mary gland appears to fall within the critical range 
then the tissue concentration is appreciably higher required for the activation of PFKl [3,12-141. The 
and falls within the range reported for liver [3,12]. tissue content of AMP also increases 2-fold over 
Also shown in table 1 is the activity of PFKl the same time span (table 2). The combined effect 
measured at these same stages of the lactation cycle of these two changes may be highly significant in 
and a striking positive correlation is observed bet- the control of glycolytic flux in the mammary 
ween the activity of PFKl and the measured gland since, as discussed in [4], the effect of AMP, 
amount of Fru-2,6-P2 in the mammary gland. The which acts on PFKl, PFK2 and fructose-1,6-bis- 
quotient PFK/Fru-2,6-Pz remains constant at the 3 phosphatase, is remarkably synergistic with that of 
stages of the lactation cycle studied here (table 1). Fru-2,6-P2. 
3.2. Changes in the metabolite profile of 
mammary gland during lactation 
A number of effecters, both positive and 
negative, have been shown to act on each of PFKl, 
PFK2, fructose-l ,6_bisphosphatase and fructose- 
2,6-bisphosphatase. The tissue content of some of 
these, at different stages of the lactation cycle, is 
shown in table 2. 
There is a significant rise, 2-fold, in the 
Fru-2,6-P2 content of mammary gland from late 
Citrate is an inhibitor of both PFKl and PFK2. 
The concentration of citrate in the mammary gland 
falls significantly during lactation. At 14 days lac- 
tation it is about half the value found in the mam- 
mary gland from pregnant rats (table 2) and ap- 
proximates to the Ki for inhibition of PFKl. The 
PFKl of mammary gland is relatively sensitive to 
citrate inhibition and a Ki value of 0.2 mM has 
been reported for citrate inhibition of this enzyme 
[lo]. It has been shown that the mechanism of 
citrate inhibition of rat mammary gland PFKl in- 
Table 2 
Changes in metabolites involved in the regulation of PFKl and PFK2 in rat mammary gland from pregnancy to lactation 
Pregnant Lactating 14 days Effect of 
(20 days) lactation/ change on 
1 day 14 days 20 days 
pregnancy PFKl PFK2 
((TJO) (P) 
Glucose 6-phosphate 193 * 21 220 * 39 190 +- 24 98 NS 
Fructose 6-phosphate 73 f 9 68 zk 9 62 + 8 85 NS 
Fru-1,6-P2 42 f 4 44 + 4 44 + 5 104 NS 
Fru-2,6-P2 5.2 zk 0.3 6.2 + 0.6 11.6 k 1.1 223 <O.OOl + 
Glycerol 3-phosphate 263 + 33 578 f 62 787 f 90 300 <O.OOl 
Phosphoenolpyruvate 13 + 1.1 11 * 1.3 12 + 2.0 92 NS 
Citrate 800 * 79 538 + 55 400 + 36 50 <O.OOl t + 
ATP 1450 Z!I 360 1930 + 380 1470 +- 291 101 NS 
AMP 540 + 41 507 + 48 1180 Ic 212 219 <O.Ol t Cyclic AMP 3.05 f 0.05 1.44 f 0.05 0.60 + 0.04 20 . Ol : 
The values (expressed as nmol/ml intracellular water) given are the means + SE of 8 values with the exception of those 
of Fru-2,6-P2 which each contain 5 values. The calculation of metabolite content/ml intracellular water is given in [7]. 
The percentage change in metabolites during lactation is given in column 4, expressed as metabolite content at 14 days 
lactation/content of 20 days pregnant x 100. Fisher’s P values are given for the change from 20 days pregnancy to 14 
days lactation; NS, not significant. The expected effect of the change in metabolite profile with lactation on the activities 
of PFKl and PFK2 is shown in the last column. Values for cyclic AMP are calculated from the data in (81, and for 
some phosphorylated sugars from [7] 
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volves potentiation of ATP inhibition and a rise in 
the K, for fructose 6phosphate [IO]. Since citrate 
is also an inhibitor of PFK2 [3,4] it is apparent hat 
the sharp fall in citrate concentration in the lac- 
tating gland could be a major effector in increasing 
the glycolytic flux. 
Glycerol 3phosphate has been reported to ac- 
tivate the phosphatase cleaving Fru-2,6-P2 [3,4]. 
The 3-fold increase in the content of this in- 
termediate during lactation could be a significant 
factor in the down-regulation of Fru-2,6-Pz in the 
lactating mamm~y gland. 
An important factor in the regulation of liver 
Fru-2,6-Pz is the phosphorylation state of PFK2 
and fructose-2,6_bisphosphatase [3,4], these en- 
zymes being regulated by cyclic AMP-dependent 
protein kinases. If a similar mechanism operates in 
the mammary gland then the activity of adenylate 
cyclase and the tissue content of cyclic AMP would 
be important in the regulation of Fru-2,6-P2 and 
glycolytic flux. Authors in [S] have shown a ?I-fold 
decrease in cyclic AMP content/g mammary tissue 
from late pregnancy to the height of lactation. 
Calculated per ml of intracellular water this is 
equivalent to a 5-fold decrease in metabolite con- 
tent (see table 2). There is also a lo-fold decrease 
in mammary gland adenylate cyclase activity from 
20 days pregnancy to 16 days lactation [8]. 
Other sugar phosphates, fructose 6-phosphate, 
Fru-1 ,6-Pz, phosphoe~o~pyruvate, and ATP, 
which are involved in the regulation of PFKI 
and/or PFK2 remain relatively unchanged in the 
rat mammary gland in the transition from late 
pregnancy to the height of lactation and therefore, 
presumably, play little direct role in regulating the 
glycolytic flux. 
4. DISCUSSION 
The present metabolite data suggest a possible 
mechanism for the coordination of biosynthetic 
routes in the lactation cycle in the rat mammary 
gland. Milk secretion involves the synthesis of pro- 
tein, fat and lactose, all processes requiring in- 
creased generation of ATP and, in the case of lipid 
synthesis, of acetyl-CoA and glycerol 3-phosphate, 
requirements necessitating an increased flux 
through the glycolytic route and PFKl. 
A number of the changes associated with in- 
creased biosynthetic pathways provide signals for 
increased flux through PFKI. Thus, one product 
of the activation of amino acids for protein syn- 
thesis is AMP, which increases harply during lac- 
tation and provides a positive effector of both 
PFKl and PFK2, the activity of PFKl being 
especially enhanced because of the synergistic ef- 
fect of the AMP and the Fru-2,6-Pz produced by 
PFK2 [4]. Similarly, the increased utilization of 
citrate for fatty acid synthesis and its secretion into 
milk (which has a high content of this metabolite) 
lower the intracellular level of citrate and this, 
again, provides a mechanism for increased activity 
of PFKl and PFK2, this time by the removal of a 
potent inhibitor [3,4, lo]. 
The fall in the tissue content of cyclic AMP [8] 
will have widespread effects via its action on cyclic 
AMP-dependent protein kinases (see [15]). In par- 
ticular, the low-phosphate form of PFKl in liver 
has been shown [14] to be much less sensitive to in- 
hibition by ATP and citrate, shows a lower Km for 
fructose 6-phosphate and is more sensitive to ac- 
tivation by AMP and Fru-2,6-P2 than the high- 
phosphate form, all properties which, if applicable 
to the mamm~y gland enzyme, would lead to a 
greatly increased flux through PFKl in lactation. 
In addition, the opposing effects of cyclic AMP on 
PFK2 and on fructose-2,6-bisphosphatase [3,4] 
would serve to increase the tissue level of 
Fru-2,6-Pt and hence amplify the stimulation of 
PFKl. 
Further, the low-phosphate form of acetyl-CoA 
carboxylase, i.e., the activated form [16], may be 
linked to the fall in the tissue content of citrate in 
lactation as may, also, the low-phosphate form of 
ATP-citrate lyase [17] although the physioIogica1 
significance of the dephosphorylation of this en- 
zyme is not yet clear. 
All these changes provide a coordinated pattern 
of modulation of PFKl which would have the ef- 
fect of greatly stimulating the glycolytic flux, via 
activation of the rate-limiting enzyme of the 
pathway, and of providing energy and substrates 
for the synthesis of milk components, so allowing 
the gland to respond to the increasing requirements 
of the growing pups. 
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